ClinicalTrials.gg
CompletedNCT06208124Updated May 28, 2025

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

A Phase 1/2 interventional study of IMM-6-415 in Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma and Non-small Cell Lung Cancer, sponsored by Immuneering Corporation. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Immuneering Corporation · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
1,998th of 3,001
30 · median 56
Started
2024
with 157 others
Phase 1/2
487 of 3,374
118 open now
Registered
2,966th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,998th largest by enrollment of the 3,001 interventional ones that give a count, is one of 158 that started in 2024, is one of 487 in phase 1/2, and was the 2,966th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.

Read the detailed description

The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-6-415 to further explore the anti-tumor activity of IMM-6-415 as monotherapy in Phase 2a tumor-specific cohorts. Patients will be self-administering IMM-6-415 on a daily basis for up to 16 cycles (21-day cycles). During the first 2 cycles, PK and PD will be assessed. Solid tumor types with RAS/RAF mutations are eligible.

03

Conditions studied

  • Advanced Solid Tumor (Phase 1)
  • Pancreas Adenocarcinoma
  • Non-small Cell Lung Cancer
  • Malignant Melanoma (Cutaneous)

Keywords

  • pan-RAS
  • pan-RAF
  • KRAS
  • NRAS
  • HRAS
  • BRAF
  • targeted therapy
  • metastatic therapy
  • RAS
  • RAF
  • adenocarcinoma
  • MEK
  • dual MEK
  • G12A
  • G12C
  • G12D
  • G12F
  • G12V
  • Q61H
  • Q61K
  • Q61R
  • Q61L
  • A146T
  • A146V
  • K117N
  • Mitogen-Activated Protein Kinase (MAPK)
  • V600E
  • V600K
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • >16 weeks
  • Part 1: or cytologically confirmed diagnosis of a locally advanced unresectable or solid tumor harboring RAS (NRAS, KRAS, or HRAS)- or RAF- (ARAF, BRAF, RAF1) activating mutations, as documented by genomic analysis. Results of mutation analysis must be available prior to participant enrollment. A prior genomics report from archival tissues or liquid demonstrating mutation is acceptable
  • Part 2: Histologically or cytologically confirmed diagnosis of one of the following locally advanced unresectable or metastatic solid tumor malignancies: pancreatic adenocarcinoma, RASmut melanoma, Class I BRAFmut melanoma, RASmut NSCLC, other RASmut GI cancers (aside from CRC) or any other RAFmut solid tumor as documented by genomic analysis. Results of mutation analysis must be available prior to participant enrollment. A prior genomics report from archival tissues or liquid biopsy demonstrating mutation is acceptable
  • Participants must have received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease and in the assessment of the Investigator, would be unlikely to tolerate or derive benefit from other treatment options
  • Participants previously treated with codon-specific inhibitors of KRAS (including agents) are eligible
  • KRASG12C mutant participants must have received prior treatment with a KRASG12C inhibitor for any approved indication
  • Radiologic evidence of (i.e., at least 1 target lesion) according to 1.1 criteria
  • performance status 0 or 1.
  • Participant has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Inability to swallow oral medications.
  • Symptomatic, untreated, or actively progressing known central nervous system .
  • Uncontrolled pleural or pericardial effusion or ascites requiring repeated drainage more than once every 28 days. In dwelling catheters are allowed.
  • History of severe COVID-19 infection resulting in current need of supplemental O2 therapy to maintain resting oxygen saturations ≥90%.
  • Presence of ongoing toxicities related to prior anticancer therapy that have not resolved to Grade ≤1 and are not otherwise allowed
  • Impaired cardiac function or cardiac disease
  • Uncontrolled intercurrent illness including but not limited to poorly controlled diabetes or any medical condition determined by the Investigator to be a risk
  • History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. History of clinically significant serous retinopathy, central serous chorioretinopathy or retinal edema.
  • History of rhabdomyolysis within 3 months prior to Study Day 1
  • -infected participant must be on anti-retroviral therapy and have a well-controlled HIV infection/disease
  • Participants with a history of infection no longer requiring treatment are eligible; participants with a history of infection are eligible if HCV viral load is undetectable at screening.
  • Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    IMM-6-415

    Dose Escalation and Dose Expansion

    Drug: IMM-6-415

Interventions

  • DrugIMM-6-415

    Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.

06

What researchers measure

Primary outcomes

  1. Phase 1/2a: Adverse Events

    Number of participants with adverse events

    Time frame: From treatment initiation through 30 days following the last IMM-6-415 dose

  2. Phase 1: Dose-Limiting Toxicities (DLT)

    Number of participants with dose-limiting toxicities

    Time frame: The first 21 days of study treatment

  3. Phase 1: Recommended Phase 2 Dose (RP2D) candidate

    Selection of candidate RP2D to take forward into Ph2a

    Time frame: Initiation of study treatment through 21 days (up to approximately 18 months)

  4. Phase 1: Maximum Observed Plasma Concentration of IMM-6-415

    Cmax

    Time frame: After 9 weeks (3 Cycles) of study treatment

  5. Phase 1: Time to Reach Maximum Observed Plasma Concentration of IMM-6-415

    Tmax

    Time frame: After 9 weeks (3 Cycles) of study treatment

  6. Phase 1: Area Under Plasma Concentration (AUC) Time Curve of IMM-6-415

    AUC0-t

    Time frame: After 9 weeks (3 Cycles) of study treatment

  7. Phase 1: Pharmacodynamic (PD) Activity of IMM-6-415 Plasma Concentrations Over Time

    Surrogate PD Biomarker Assay, pERK

    Time frame: After 9 weeks (3 Cycles) of study treatment

  8. Phase 2a: Overall Response Rate (ORR)

    The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria

    Time frame: After up to 48 weeks (16 cycles) of study treatment

Secondary outcomes

  1. Phase 2a: Maximum Observed Plasma Concentration of IMM-6-415

    Cmax

    Time frame: After 9 weeks (3 Cycles) of study treatment

  2. Phase 2a: Time to Reach Maximum Observed Plasma Concentration of IMM-6-415

    Tmax

    Time frame: After 9 weeks (3 Cycles) of study treatment

  3. Phase 2a: Area Under Plasma Concentration (AUC) Time Curve of IMM-6-415

    AUC0-t

    Time frame: After 9 weeks (3 Cycles) of study treatment

  4. Phase 2a: Disease Control Rate (DCR)

    The proportion of participants who have a best overall response (BOR) of stable disease (SD) or better

    Time frame: After 12 weeks (4 Cycles) of study treatment

  5. Phase 2a: Progression Free Survival (PFS)

    The time interval between study treatment start and disease progression or death due to any cause.

    Time frame: Up to approximately 2 years

  6. Phase 2a: Duration of Response (DOR)

    The time interval between an assessment of partial response (PR) or better and disease progression or death due to any cause.

    Time frame: Up to approximately 2 years

  7. Phase 2a: Landmark 3-Month Survival

    The proportion of participants who are still alive after three months on study

    Time frame: After 3 months of study participation.

  8. Phase 2a: Landmark 6-Month Survival

    The proportion of participants who are still alive after six months on study

    Time frame: After 6 months of study participation

  9. Phase 2a: Overall Survival (OS)

    The time interval between study treatment start and death due to any cause

    Time frame: Up to approximately 2 Years

07

Study locations

5 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • City of Hope
    Duarte, California 91010, United States
  • Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2025, 14 months.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 14 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 17, 2024
StartActual
Feb 27, 2024
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 30, 2025
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06208124
Lead sponsor
Immuneering Corporation
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
Feb 27, 2024
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Last update
May 28, 2025

Study contacts

Vinny Hayreh, MD
study director · Immuneering Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion